UroGen Pharma URGN Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$23.57M+10.6% | -$26.36M+20.9% | -$33.35M+33.2% | -$49.94M-13.9% | -$43.84M-16.9% | ||
| $75K0.0% | $75K-25.0% | $100K0.0% | $100K+38.9% | $72K+5.9% | ||
| $4.63M+47.8% | $3.13M+3.4% | $3.03M+10.8% | $2.73M-10.9% | $3.07M-7.1% | ||
| $22.33M+66.9% | $13.38M— | —— | —— | -$664K— | ||
| $4.46M-45.1% | $8.12M+570% | $1.21M+363% | -$462K+71.8% | -$1.64M-200% | ||
| $7.63M+394% | $1.54M+132% | -$4.79M-848% | $640K-77.9% | $2.89M-62.7% | ||
| -$3.68M-253% | $2.4M— | —— | $4.68M+230% | -$3.6M— | ||
| $2.33M— | —— | $5.96M+1,286% | $430K+297% | -$218K— | ||
| $0+100% | -$1K+99.6% | -$263K+37.5% | -$421K-187% | $483K+142% | ||
| $577K-4.5% | $604K+8.1% | $559K+8.3% | $516K+21.4% | $425K+78.6% | ||
| -$53K— | —— | -$628K-3.6% | -$606K+17.9% | -$738K-80.9% | ||
| $1.97M+1,894% | $99K— | —— | $400K+7.0% | $374K— | ||
| -$45.32M-18.2% | -$38.33M+9.3% | -$42.27M-6.1% | -$39.83M+5.2% | -$42.02M-209% | ||
| $54K+218% | $17K-80.5% | $87K-38.3% | $141K+220% | $44K-61.7% | ||
| $4.15M-85.3% | $28.27M-29.7% | $40.21M+32.5% | $30.34M-25.0% | $40.43M-42.2% | ||
| -$20.69M-175% | $27.72M-11.7% | $31.4M+10.5% | $28.41M+209% | -$25.96M— | ||
| $65.35M— | $0— | —— | —— | $0-100% | ||
| $0-100% | $31.83M+299% | $7.97M+199,350% | -$4K-200% | $4K— | ||
| —— | $463.75K0.0% | $463.75K0.0% | $463.75K0.0% | $463.75K— | ||
| $65.2M+108% | $31.32M+279% | $8.27M+2,695% | $296K+771% | $34K-52.1% | ||
| -$800K— | —— | -$2.6M+76.6% | -$11.12M+83.6% | -$67.95M-244% | ||
| -$26K-135% | $75K-53.1% | $160K-81.5% | $866K+11.9% | $774K-42.1% | ||
| $1.97M+1,894% | $99K— | —— | $400K+7.0% | $374K— | ||
| -$3.68M-253% | $2.4M— | —— | $4.68M+230% | -$3.6M— | ||
| -$53K— | —— | -$628K-3.6% | -$606K+17.9% | -$738K-80.9% | ||
| $0+100% | -$1K+99.6% | -$263K+37.5% | -$421K-187% | $483K+142% | ||
| $4.86M+90.5% | $2.55M+3,706% | $67K— | —— | $4.14M+179% | ||
| $577K-4.5% | $604K+8.1% | $559K+8.3% | $516K+21.4% | $425K+78.6% | ||
| $4.15M-85.3% | $28.27M-29.7% | $40.21M+32.5% | $30.34M-25.0% | $40.43M-42.2% | ||
| —— | $463.75K0.0% | $463.75K0.0% | $463.75K0.0% | $463.75K— | ||
| $1.06M-16.6% | $1.27M-13.7% | $1.47M-26.8% | $2.01M+207% | -$1.89M-131% | ||
| $321K— | —— | —— | —— | $0— | ||
| -$53K— | —— | -$628K-3.6% | -$606K+17.9% | -$738K-80.9% | ||
| —— | $28K0.0% | $28K0.0% | $28K0.0% | $28K-81.2% | ||
| $0— | —— | —— | —— | $3.13M— | ||
| $60K-89.5% | $571K-83.7% | $3.5M+166% | $1.31M-35.8% | $2.05M-11.9% | ||
| $0— | —— | —— | —— | $3.13M— | ||
| -$45.37M-18.3% | -$38.34M+9.5% | -$42.36M-6.0% | -$39.97M+5.0% | -$42.07M-206% | ||
| -$45.37M-18.3% | -$38.34M+9.5% | -$42.36M-6.0% | -$39.97M+5.0% | -$42.07M-206% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does UroGen Pharma generate?
- UroGen Pharma (URGN) generated -$165.7M in operating cash flow over the trailing twelve months.
- What is UroGen Pharma's free cash flow?
- After $299.0K of capital expenditures, UroGen Pharma's free cash flow was -$166.0M over the trailing twelve months, down 54.6% year over year.
- Where does UroGen Pharma's cash flow data come from?
- Every line is extracted from UroGen Pharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
